Most human immunodeficiency virus (HIV) vaccine trials have lacked efficacy and empirical
vaccine lead targets are scarce. Thus far, the only independent correlate of reduced risk of …

A productive HIV-1 infection in humans is often established by transmission and propagation
of a single transmitted/founder (T/F) virus, which then evolves into a complex mixture of …

Introduction An efficacious HIV vaccine will need to elicit a complex package of innate,
humoral, and cellular immune responses. This complex package of responses to vaccine …

The RV144 vaccine trial revealed a correlation between reduced risk of HIV infection and
the level of nonneutralizing-antibody (Ab) responses targeting specific epitopes in the …

A productive HIV-1 infection is often established by a single transmitted/founder (T/F) virus,
which then evolves into a complex mixture of variants during the lifetime of infection. An …

Antibodies against the HIV-1 V1V2 loops were the only correlate of reduced infection risk in
the RV144 vaccine trial, highlighting the V1V2 loops as promising targets for vaccine design …

Background: HIV is characterized by high levels of genetic variability, including increased
numbers of heterogeneous sequences of the envelope region. Therefore, studying genetic …

Cells | Free Full-Text | Correction: Trinh, HV, et al. Humoral Response to the HIV-1 Envelope
V2 Region in a Thai Early Acute Infection Cohort. Cells 2019, 8, 365 Next Article in Journal …

HIV-1 continues to be a public health concern, causing 1.8 million new infections per year
globally. Despite four decades of research around the globe, an effective HIV-1 vaccine is …

Vaccines are largely hailed as the single most impactful public health intervention.
Empirically developed first-generation vaccines have demonstrated that vaccine-elicited …